Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, includin… Read more
Q linea AB - Asset Resilience Ratio
Q linea AB (QLINEA) has an Asset Resilience Ratio of 69.82% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Q linea AB's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Q linea AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr258.11 Million | 69.82% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr258.11 Million | 69.82% |
Asset Resilience Insights
- Very High Liquidity: Q linea AB maintains exceptional liquid asset reserves at 69.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Q linea AB Industry Peers by Asset Resilience Ratio
Compare Q linea AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
|
Osang Healthcare Co.,Ltd
KQ:036220 |
Medical Devices | 9.34% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
Annual Asset Resilience Ratio for Q linea AB (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Q linea AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 69.82% | Skr258.11 Million | Skr369.67 Million | +52.48pp |
| 2024-12-31 | 17.34% | Skr25.66 Million | Skr147.99 Million | -17.98pp |
| 2023-12-31 | 35.33% | Skr81.95 Million | Skr231.98 Million | +0.08pp |
| 2022-12-31 | 35.24% | Skr73.09 Million | Skr207.39 Million | -0.34pp |
| 2021-12-31 | 35.58% | Skr166.03 Million | Skr466.63 Million | -38.86pp |
| 2020-12-31 | 74.45% | Skr306.89 Million | Skr412.23 Million | +19.30pp |
| 2019-12-31 | 55.15% | Skr206.48 Million | Skr374.41 Million | -38.43pp |
| 2018-12-31 | 93.58% | Skr504.44 Million | Skr539.07 Million | +57.77pp |
| 2017-12-31 | 35.81% | Skr6.59 Million | Skr18.40 Million | -- |